Digital therapeutic programs provide clinically validated outcomes and help people with type 2 diabetes.

Fitterfly Diabetes CGM Digital Therapeutics Program for Glycemic Control and Weight Management in People With Type 2 Diabetes Mellitus
Go to source).
Diabetes Prevention Through Digital Therapeutics
The researchers found that, at the end of the 90-day program, about 85% of all participants observed an average reduction of 1.2% in hemoglobin A1c (HbA1c) levels, an important indicator of glycemic control. The reduction was even higher, at about 2.6%, for those participants who started the program with an HbA1c level greater than 9%. The study participants also lost an average of 2.05 kg body weight, and their BMI reduced by 0.74 kg/m2.Dr. Arbinder Singal, CEO and cofounder of Fitterfly, said, “Type 2 diabetes is a huge health care concern in India. With the use of newer tools such as digital therapeutics now getting adopted by people and enterprise partners, and getting prescribed by physicians, we are bridging the gap for behavior change.”
The program's easy-to-use app interface and personalized approach make it a promising option for individuals looking to improve their health and manage Diabetes effectively.
Interestingly, the study also found that participants who engaged more with the app throughout the program’s duration had better clinical outcomes, especially with regard to weight reduction. Thus, Fitterfly’s CGM program could be a valuable tool for health care professionals in managing type 2 diabetes and supporting weight loss goals.
Reference:
- Fitterfly Diabetes CGM Digital Therapeutics Program for Glycemic Control and Weight Management in People With Type 2 Diabetes Mellitus: Real-world Effectiveness Evaluation- (https://diabetes.jmir.org/2023/1/e43292
MEDINDIA














